8.74 0.00 (0.00%)
After hours: 5:04PM EDT
|Bid||8.74 x 900|
|Ask||8.75 x 2200|
|Day's Range||8.60 - 9.00|
|52 Week Range||7.81 - 26.10|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.14|
How far off is AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) from its intrinsic value? Using the most recent financial...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
The FDA’s recent approval of a second drug to treat a female sexual disorder means competition for one Triangle drug-maker, but also the growth of an industry its CEO hopes will drive success for her firm.
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
on Monday jumped and then pulled back after the biopharma was cleared by the U.S. Food and Drug Administration to market a drug to treat weakened sexual desire in women. Palatin shares closed down 9.7% at $1.21. The FDA cleared Vyleesi, a treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder, Palatin said.
It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).
Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc.'s treatment for hypoactive sexual desire disorder (HSDD) triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for AMAG's new drug application (NDA) for Vyleesi, which was developed by Palatin. AMAG's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with AMAG, Palatin is also entitled to receive royalties on sales, ranging from high single-digit to low double-digit percentage ranges, and other milestone payments based on escalating annual sales thresholds. Palatin's stock has rallied 23% over the past 12 months and AMAG shares have tumbled 59%, while the S&P 500 has gained 7.1%.
Biotech stocks came made upward moves last week after a rangebound period. Among big pharma companies, Merck & Co., Inc. (NYSE: MRK ) was a standout gainer, notching up 52-week highs in successive sessions, ...
The U.S. Food and Drug Administration late Friday approved a drug to treat low libido in women, and shares of the company slated to market the medication, AMAG Pharmaceuticals Inc. , shot more than 16% in the extended session. The drug, Vyleesi, is aimed at premenopausal women in whom low sex drive causes distress. It comes in an auto-injecting pen that can be used ahead of sexual activity. Vyleesi is expected to be commercially available in September. AMAG licensed Vyleesi from Palatin Technologies Inc. and under the terms of their agreement the FDA approval triggers a $60 million payment to Palatin, plus tiered royalties tied to sales milestones. Shares of Palatin rallied 30% in the extended session. Both stocks ended the regular trading day more than 4% higher.
Amag Pharmaceuticals Inc. has received regulatory approval to begin selling Vyleesi, a drug designed to address hypoactive sexual disorder, a condition in which causes low sexual desire and distress in an estimated one in 10 women.
AMAG Pharmaceuticals, Inc. (AMAG) announced today that the U.S. Food and Drug Administration (FDA) has approved Vyleesi™ (bremelanotide injection), a melanocortin receptor agonist, to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by low sexual desire that causes distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The daily On-Balance-Volume (OBV) has been in a downtrend the past 12 months and the Moving Average Convergence Divergence (MACD) oscillator has spent most of the past year below the zero line in bear territory. In this long-term weekly chart of AMAG, below, we can see the price action all the way back to 1987. The weekly OBV line is bearish and so is the MACD oscillator.
WALTHAM, Mass., May 29, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a small-cap stock with a market capitalization of US$349m. While investors...
WALTHAM, Mass., May 17, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 22,.